Tygh Capital Management Inc. Has $8.90 Million Holdings in Charles River Laboratories Intl. Inc (NYSE:CRL)

Tygh Capital Management Inc. raised its position in shares of Charles River Laboratories Intl. Inc (NYSE:CRL) by 117.7% in the third quarter, according to its most recent filing with the SEC. The firm owned 67,261 shares of the medical research company’s stock after purchasing an additional 36,371 shares during the quarter. Charles River Laboratories Intl. makes up approximately 1.6% of Tygh Capital Management Inc.’s investment portfolio, making the stock its 24th largest holding. Tygh Capital Management Inc. owned approximately 0.14% of Charles River Laboratories Intl. worth $8,903,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Squar Milner Financial Services LLC increased its position in Charles River Laboratories Intl. by 253.2% during the 3rd quarter. Squar Milner Financial Services LLC now owns 219 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 157 shares during the period. Hussman Strategic Advisors Inc. acquired a new stake in Charles River Laboratories Intl. during the 3rd quarter valued at approximately $33,000. Flagship Harbor Advisors LLC increased its position in Charles River Laboratories Intl. by 132.1% during the 2nd quarter. Flagship Harbor Advisors LLC now owns 318 shares of the medical research company’s stock valued at $45,000 after purchasing an additional 181 shares during the period. CWM LLC grew its position in shares of Charles River Laboratories Intl. by 75.9% during the 3rd quarter. CWM LLC now owns 387 shares of the medical research company’s stock worth $51,000 after buying an additional 167 shares during the period. Finally, Steward Partners Investment Advisory LLC acquired a new stake in shares of Charles River Laboratories Intl. during the 2nd quarter worth approximately $69,000. 94.31% of the stock is owned by institutional investors and hedge funds.

Shares of CRL stock traded up $1.50 during trading hours on Monday, hitting $132.01. 295,916 shares of the company were exchanged, compared to its average volume of 360,440. The firm has a market cap of $6.39 billion, a P/E ratio of 21.89, a P/E/G ratio of 2.00 and a beta of 1.08. Charles River Laboratories Intl. Inc has a fifty-two week low of $103.00 and a fifty-two week high of $149.07. The company has a debt-to-equity ratio of 1.47, a quick ratio of 1.38 and a current ratio of 1.59. The company has a 50 day simple moving average of $132.15 and a two-hundred day simple moving average of $133.41.

Charles River Laboratories Intl. (NYSE:CRL) last issued its earnings results on Wednesday, November 6th. The medical research company reported $1.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.64 by $0.05. Charles River Laboratories Intl. had a return on equity of 22.01% and a net margin of 8.94%. The company had revenue of $668.00 million for the quarter, compared to analysts’ expectations of $674.08 million. During the same period last year, the business earned $1.53 EPS. Charles River Laboratories Intl.’s quarterly revenue was up 14.1% compared to the same quarter last year. As a group, sell-side analysts expect that Charles River Laboratories Intl. Inc will post 6.53 EPS for the current fiscal year.

CRL has been the subject of several recent analyst reports. ValuEngine downgraded shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Zacks Investment Research downgraded shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research report on Monday, October 21st. Credit Suisse Group set a $138.00 price objective on shares of Charles River Laboratories Intl. and gave the stock a “hold” rating in a research report on Friday, September 13th. UBS Group reduced their price objective on shares of Charles River Laboratories Intl. from $147.00 to $145.00 and set a “neutral” rating for the company in a research report on Thursday. Finally, SunTrust Banks raised their price objective on shares of Charles River Laboratories Intl. from $156.00 to $162.00 and gave the stock a “buy” rating in a research report on Monday, September 16th. Eight investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $150.50.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Further Reading: How to find the components of the quick ratio

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories Intl. Inc (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.